The Italian Medicines Agency (AIFA) will be hosting a workshop on “The role of In Silico Medicine in diabetes” on 26 May 2022.
The workshop is organised by AIFA in collaboration with the Virtual Physiological Human Institute and aims to present the state of the art of In Silico Medicine applied to the development and assessment of new treatments for diabetes.
Computational modelling and simulation in healthcare, referred to as In Silico Medicine, is a promising approach to optimise and accelerate the (pre-)clinical development of novel medicinal products, integrating efficacy and safety evidence generated by experimental studies.
In Silico Medicine is being extensively investigated and an early and continuous dialogue is pivotal between regulatory authorities, academia and industry to analyse the potential applications of this approach and define an appropriate regulatory framework, which will ultimately benefit the patient.
The event can be attended remotely by following the live stream on: